Table 2.
Clinical characteristics of the neoadjuvant chemotherapy (NAC) and non-NAC patients.
| Variables | Non-NAC (n = 50) | NAC (n = 29) | Total (n = 79) | |
|---|---|---|---|---|
| Age (years) | 54.36 ± 8.48 | 50.38 ± 8.62 | 52.90 ± 8.69 | |
| Age of menarche(years) | 14.94 ± 1.60 | 14.28 ± 1.60 | 14.70 ± 1.62 | |
| Menopausal status (%) | Premenopausal | 22 (44.00) | 13 (44.83) | 35 (44.30) |
| Postmenopausal | 28 (56.00) | 16 (55.17) | 44 (55.70) | |
| Status of hormone receptor of breast tumors (%) | ER+ | 30 (60.00) | 19 (65.52) | 49 (62.03) |
| ER− | 20 (40.00) | 10 (34.48) | 30 (37.97) | |
| HER2+ | 20 (40.00) | 10 (34.48) | 30 (37.97) | |
| HER2− | 30 (60.00) | 19 (65.52) | 49 (62.03) | |
| Non-TNBC | 40 (80.00) | 24 (82.76) | 64 (81.01) | |
| TNBC | 10 (20.00) | 5 (17.24) | 15 (18.99) | |
| Tumor grade (%) | Grade 1/2 | 28 (56.00) | 18 (62.07) | 46 (58.23) |
| Grade 3 | 20 (40.00) | 9 (31.03) | 29 (36.71) | |
| Unknown | 2 (4.00) | 2 (6.90) | 4 (5.06) | |